PubRank

B A Keyt

Author PubWeight™ 47.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 16.24
2 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998 8.30
3 Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995 2.35
4 High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991 2.02
5 Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998 1.89
6 Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 1998 1.53
7 The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997 1.46
8 A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993 1.20
9 Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch Biochem Biophys 1997 1.04
10 Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. J Pharmacol Exp Ther 1998 1.01
11 Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins 1996 0.98
12 New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995 0.93
13 Making tissue-type plasminogen activator more fibrin specific. Protein Eng 1993 0.84
14 Identification of carbohydrate structures in glycoprotein peptide maps by the use of LC/MS with selected ion extraction with special reference to tissue plasminogen activator and a glycosylation variant produced by site directed mutagenesis. Anal Chem 1993 0.83
15 A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993 0.82
16 A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994 0.82
17 Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000 0.82
18 Study of the primary structure of recombinant tissue plasminogen activator by reversed-phase high-performance liquid chromatographic tryptic mapping. J Chromatogr 1989 0.79
19 Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology. Cold Spring Harb Symp Quant Biol 1986 0.78
20 Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow. Ann Biomed Eng 1998 0.77
21 Visualization of thrombi in pulmonary arteries with radiolabeled, enzymatically inactivated tissue-type plasminogen activator. Circulation 1995 0.76
22 Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin. Br J Haematol 2000 0.76
23 1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor. Protein Sci 1997 0.76
24 Scintigraphic visualization of pulmonary thrombi with 123I-YPACK-TNK-tPA. Coron Artery Dis 1995 0.75
25 Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase. Thromb Haemost 1996 0.75
26 Locating the unpaired cysteine of tissue-type plasminogen activator. Protein Eng 1996 0.75